Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia 9Leukemia, Lymphocytic, Chronic, B-Cell 8Myelodysplastic Syndromes 5Myeloproliferative Disorders 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Multiple Myeloma 3Lymphoma, Follicular 3Leukemia, Myelomonocytic, Chronic 3Anemia, Refractory, with Excess of Blasts 3Sarcoma 2Neuroblastoma 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Large Granular Lymphocytic 2Anemia, Refractory 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Salivary Gland Neoplasms 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1

Interventions

Cyclophosphamide 13fludarabine 11Mycophenolic Acid 9Busulfan 8fludarabine phosphate 7Tacrolimus 7pirtobrutinib 6Whole-Body Irradiation 6Rituximab 6Melphalan 6Imatinib Mesylate 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Granulocyte Colony-Stimulating Factor 4Azacitidine 4venetoclax 3nilotinib 3lintuzumab 3Stem Cell Transplantation 3Sirolimus 3Platelet Transfusion 3Methotrexate 3Cytarabine 3Cyclosporine 3Alemtuzumab 3vosaroxin 2ruxolitinib 2ibrutinib 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Thalidomide × Other hematologic neoplasm × Clear all
NCT00023530 2016-02-18

Blood and Marrow Transplant Clinical Research Network

National Heart, Lung, and Blood Institute (NHLBI)

Phase NA Completed
MyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Hematologic Diseases, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡